Aztreonam-avibactam：一种具有抗多药耐药肺炎克雷伯菌复合物活性的新组合。

IF 2.1 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Journal of Antibiotics Pub Date : 2025-01-07 DOI:10.1038/s41429-024-00803-6

Alicja Sękowska

{"title":"Aztreonam-avibactam：一种具有抗多药耐药肺炎克雷伯菌复合物活性的新组合。","authors":"Alicja Sękowska","doi":"10.1038/s41429-024-00803-6","DOIUrl":null,"url":null,"abstract":"Klebsiella pneumoniae complex (KPc) is a group of opportunistic pathogens that pose a serious threat to public health. Multidrug resistance is increasing, and limiting therapeutic options. Aztreonam-avibactam (AZA) is a combination of an established β-lactam with a new β-lactamase inhibitor. The aim of this study was to assess the susceptibility of multidrug-resistant KPc strains to AZA. The study included 52 ESβL-positive strains and 152 carbapenemase-positive KPc strains. The susceptibility to AZA was tested using the gradient strip method. AZA showed high activity against KPc, with MICs ranging from 0.032 to 0.75 μg ml-1 for ESβL-positive strains and from 0.016 to 2 μg ml-1 for carbapenemase-positive strains. The lowest MIC50 of AZA was obtained for VIM- and ESβL-positive strains at 0.094 μg ml-1, and MIC90 for ESβL-positive strains was 0.125 μg ml-1. AZA demonstrated excellent in vitro activity against the analysed strains, suggesting that this antibiotic may be an effective therapeutic option for treating infections caused by multidrug-resistant KPc strains.","PeriodicalId":54884,"journal":{"name":"Journal of Antibiotics","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Aztreonam-avibactam: a new combination with activity against multidrug-resistant Klebsiella pneumoniae complex.\",\"authors\":\"Alicja Sękowska\",\"doi\":\"10.1038/s41429-024-00803-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Klebsiella pneumoniae complex (KPc) is a group of opportunistic pathogens that pose a serious threat to public health. Multidrug resistance is increasing, and limiting therapeutic options. Aztreonam-avibactam (AZA) is a combination of an established β-lactam with a new β-lactamase inhibitor. The aim of this study was to assess the susceptibility of multidrug-resistant KPc strains to AZA. The study included 52 ESβL-positive strains and 152 carbapenemase-positive KPc strains. The susceptibility to AZA was tested using the gradient strip method. AZA showed high activity against KPc, with MICs ranging from 0.032 to 0.75 μg ml-1 for ESβL-positive strains and from 0.016 to 2 μg ml-1 for carbapenemase-positive strains. The lowest MIC50 of AZA was obtained for VIM- and ESβL-positive strains at 0.094 μg ml-1, and MIC90 for ESβL-positive strains was 0.125 μg ml-1. AZA demonstrated excellent in vitro activity against the analysed strains, suggesting that this antibiotic may be an effective therapeutic option for treating infections caused by multidrug-resistant KPc strains.\",\"PeriodicalId\":54884,\"journal\":{\"name\":\"Journal of Antibiotics\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-01-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Antibiotics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41429-024-00803-6\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Antibiotics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41429-024-00803-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

肺炎克雷伯菌复合体（KPc）是一组对公共卫生构成严重威胁的机会性病原体。多药耐药性正在增加，并限制了治疗选择。Aztreonam-avibactam （AZA）是一种已建立的β-内酰胺与一种新的β-内酰胺酶抑制剂的组合。本研究的目的是评估多重耐药KPc菌株对AZA的敏感性。研究纳入52株es β l阳性菌株和152株碳青霉烯酶阳性KPc菌株。采用梯度条法检测菌株对AZA的敏感性。AZA对KPc具有较高的抑制活性，es β l阳性菌株的mic值为0.032 ~ 0.75 μg ml-1，碳青霉烯酶阳性菌株的mic值为0.016 ~ 2 μg ml-1。VIM-和es β l阳性菌株的MIC50最低为0.094 μg ml-1， es β l阳性菌株的MIC90最低为0.125 μg ml-1。AZA对所分析的菌株表现出良好的体外活性，表明该抗生素可能是治疗多重耐药KPc菌株引起的感染的有效治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Aztreonam-avibactam: a new combination with activity against multidrug-resistant Klebsiella pneumoniae complex.

Klebsiella pneumoniae complex (KPc) is a group of opportunistic pathogens that pose a serious threat to public health. Multidrug resistance is increasing, and limiting therapeutic options. Aztreonam-avibactam (AZA) is a combination of an established β-lactam with a new β-lactamase inhibitor. The aim of this study was to assess the susceptibility of multidrug-resistant KPc strains to AZA. The study included 52 ESβL-positive strains and 152 carbapenemase-positive KPc strains. The susceptibility to AZA was tested using the gradient strip method. AZA showed high activity against KPc, with MICs ranging from 0.032 to 0.75 μg ml^-1 for ESβL-positive strains and from 0.016 to 2 μg ml^-1 for carbapenemase-positive strains. The lowest MIC₅₀ of AZA was obtained for VIM- and ESβL-positive strains at 0.094 μg ml^-1, and MIC₉₀ for ESβL-positive strains was 0.125 μg ml^-1. AZA demonstrated excellent in vitro activity against the analysed strains, suggesting that this antibiotic may be an effective therapeutic option for treating infections caused by multidrug-resistant KPc strains.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Antibiotics 医学-免疫学

CiteScore

6.60

自引率

3.00%

发文量

审稿时长

1 months

期刊介绍： The Journal of Antibiotics seeks to promote research on antibiotics and related types of biologically active substances and publishes Articles, Review Articles, Brief Communication, Correspondence and other specially commissioned reports. The Journal of Antibiotics accepts papers on biochemical, chemical, microbiological and pharmacological studies. However, studies regarding human therapy do not fall under the journal’s scope. Contributions regarding recently discovered antibiotics and biologically active microbial products are particularly encouraged. Topics of particular interest within the journal''s scope include, but are not limited to, those listed below: Discovery of new antibiotics and related types of biologically active substances Production, isolation, characterization, structural elucidation, chemical synthesis and derivatization, biological activities, mechanisms of action, and structure-activity relationships of antibiotics and related types of biologically active substances Biosynthesis, bioconversion, taxonomy and genetic studies on producing microorganisms, as well as improvement of production of antibiotics and related types of biologically active substances Novel physical, chemical, biochemical, microbiological or pharmacological methods for detection, assay, determination, structural elucidation and evaluation of antibiotics and related types of biologically active substances Newly found properties, mechanisms of action and resistance-development of antibiotics and related types of biologically active substances.